Introduction Oral tenofovir disoproxil fumarate/emtricitabine pre‐exposure prophylaxis
(PrEP), introduced into South Africa (SA) in 2016, has increasingly become part of HIV …

Background Adolescent girls and young women (AGYW) in South Africa are at a higher risk
of acquiring HIV. Despite the increasing availability of daily oral pre-exposure prophylaxis …

Introduction HIV incidence remains high among African adolescent girls and young women
(AGYW), who would benefit from pre‐exposure prophylaxis (PrEP). Strategies to increase …

Introduction Oral pre‐exposure prophylaxis (PrEP) has been scaled up; however, data from
real‐world settings are limited. We studied oral PrEP preference, uptake, adherence and …

Background HIV incidence among adolescents in southern Africa remains unacceptably
high. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention but there …

Background Pre-exposure prophylaxis (PrEP) is highly effective and an important prevention
tool for African adolescent girls and young women (AGYW), but adherence and persistence …

As oral tenofovir-based regimens for preexposure prophylaxis (PrEP) are adopted as
standard of care for HIV prevention, their utilization in clinical trials among women in …

Introduction Adolescent girls and young women (AGYW) in Africa have high HIV incidence
despite scale‐up of HIV testing and HIV treatment. Placebo‐controlled trials of tenofovir …

Objective: We developed the Healthy Families-PrEP intervention to support HIV-prevention
during periconception and pregnancy. We evaluated preexposure prophylaxis (PrEP) use …

Introduction Since many countries in sub‐Saharan Africa are willing to implement HIV oral
pre‐exposure prophylaxis (PrEP) for men who have sex with men (MSM), data are needed …